Ra Capital Management, L.P. - Apr 28, 2025 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Role
10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
JBIO
Transactions as of
Apr 28, 2025
Transactions value $
$0
Form type
4
Date filed
4/30/2025, 04:52 PM
Previous filing
Mar 17, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JBIO Common Stock Other +1.06M +471.03% 1.29M Apr 28, 2025 See footnotes F1, F2, F3, F4
holding JBIO Common Stock 28.2K Apr 28, 2025 See footnotes F2, F4, F5
holding JBIO Common Stock 8.89K Apr 28, 2025 See footnotes F2, F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Ra Capital Management, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On April 28, 2025, the Issuer completed the transactions contemplated by the Agreement and Plan of Merger, dated October 30, 2024, by and among the Issuer, Caribbean Merger Sub I, Inc. ("Merger Sub I"), Caribbean Merger Sub II, LLC ("Merger Sub II") and Jade Biosciences, Inc. (" Old Jade"), pursuant to which, Merger Sub I merged with and into Old Jade, with Old Jade surviving the merger as the surviving corporation (the "First Merger"), and as part of the same overall transaction, Old Jade merged with and into Merger Sub II, with Merger Sub II continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "Second Merger"). At the effective time of the First Merger, each share of Old Jade common stock was converted based on an exchange ratio (after giving effect to the Reverse Stock Split, as defined below) of 0.6311 shares of the Issuer's common stock for each share of Old Jade common stock.
F2 On April 28, 2025, the Issuer effected a 1-for-35 reverse stock split of its common stock stock (the "Reverse Stock Split"). The share counts herein reflect the reverse stock split.
F3 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F4 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F5 Held directly by the Nexus Fund.
F6 Held directly by the Account.